MR-guided focal laser ablation of the prostate: a pilot study - MR-guided focal laser ablation

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•Inclusion criteria counting for both groups:
•Newly diagnosed and biopsy proven prostate cancer
•Low risk patients (PSA <= 10 ng/mL, Gleason 3+3, cT1c - T2a)
•No previous treatment for prostate cancer
•Cancer lesion located at least 2 cm away from the neurovascular bundle
•according to Multimodality MR images
•Signed informed consent by patient
•Age 18 years or older
•Signed screening form (to determine exclusion for metal device/foreign bodies/claustrophobia);Additional inclusion criterion for patients in group A:
•Patients must be scheduled for a radical prostatectomy with a lesion of max 4 cm

•Impossibility to obtain a valid informed consent
•Patients unable to undergo MR imaging, including those with contra-indications
•Contra-indications to MR guided focal laser therapy (colitis ulcerosa, rectal pathology or abdomino perineal resection)
•Metallic hip implant or any other metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging
•Patients with evidence for nodal or metastatic disease
•Patients with an estimated Glomerular Filtration Ratio (eGFR) < 40 mL/min/1.73 m2

发起方

niversitair Medisch Centrum Sint Radboud